Shawaqfeh Bara'a, Hughes Carmel M, McGuinness Bernadette, Barry Heather E
Primary Care Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.
Faculty of Pharmacy, AL-Zaytoonah University of Jordan, Amman, Jordan.
Int J Clin Pharm. 2025 Apr;47(2):345-353. doi: 10.1007/s11096-024-01831-w. Epub 2024 Nov 25.
Anticholinergic medications and associated anticholinergic burden can impair cognitive function and increase mortality rates in patients with dementia.
To explore community pharmacists' knowledge of anticholinergic burden and perceptions of their role in anticholinergic burden management amongst patients with dementia.
A self-administered, postal questionnaire was distributed to all registered community pharmacies in Northern Ireland (n = 526) on two occasions (October and November 2022). The questionnaire comprised four sections: (1) demographics associated with pharmacists and pharmacies, (2) contact between community pharmacists and patients with dementia/their carers, and types of medication-related queries received by pharmacists, (3) understanding and knowledge about anticholinergic burden, and (4) community pharmacist role in management of anticholinergic burden in patients with dementia. Data were analysed descriptively using Stata v17.
A response rate of 15.2% (80/526) was achieved. Most contact was with patients with dementia/carers in their own homes. Community pharmacists lacked knowledge about anticholinergic burden in dementia, did not use any anticholinergic burden scales in their practice (n = 77, 96.3%), and rarely discussed anticholinergic burden with patients, carers (n = 60, 75.0%), or other healthcare professionals (n = 42, 52.5%). However, they were positive about their role in future interventions and saw value in managing anticholinergic burden in patients with dementia as part of a multidisciplinary primary healthcare team (n = 67; 83.3%).
Despite the low response rate, the study findings have highlighted community pharmacists' willingness to contribute to the management of anticholinergic burden in patients with dementia. Further research is required to understand how this can be achieved.
抗胆碱能药物及其相关的抗胆碱能负担会损害痴呆患者的认知功能并增加死亡率。
探讨社区药剂师对抗胆碱能负担的了解以及他们对在痴呆患者抗胆碱能负担管理中所扮演角色的看法。
在2022年10月和11月分两次向北爱尔兰所有注册社区药房(n = 526)发放了一份自填式邮政问卷。问卷包括四个部分:(1)与药剂师和药房相关的人口统计学信息,(2)社区药剂师与痴呆患者/其护理人员之间的接触以及药剂师收到的药物相关问题类型,(3)对抗胆碱能负担的理解和认识,(4)社区药剂师在痴呆患者抗胆碱能负担管理中的角色。使用Stata v17对数据进行描述性分析。
回复率为15.2%(80/526)。大多数接触是在痴呆患者/护理人员家中进行的。社区药剂师缺乏对痴呆症中抗胆碱能负担的了解,在实践中未使用任何抗胆碱能负担量表(n = 77,96.3%),并且很少与患者、护理人员(n = 60,75.0%)或其他医疗保健专业人员(n = 42,52.5%)讨论抗胆碱能负担。然而,他们对自己在未来干预中的角色持积极态度,并认为作为多学科初级医疗团队的一部分管理痴呆患者的抗胆碱能负担具有价值(n = 67;83.3%)。
尽管回复率较低,但研究结果突出了社区药剂师愿意为痴呆患者抗胆碱能负担的管理做出贡献。需要进一步研究以了解如何实现这一点。